Abstract:Background The failure of spontaneous resolution underlies chronic inflammatory conditions, including microvascular complications of diabetes such as diabetic kidney disease. The identification of endogenously generated molecules that promote the physiologic resolution of inflammation suggests that these bioactions may have therapeutic potential in the context of chronic inflammation. Lipoxins (LXs) are lipid mediators that promote the resolution of inflammation. Methods We investigated the potential of LXA 4 and a synthetic LX analog (Benzo-LXA 4 ) as therapeutics in a murine model of diabetic kidney disease, ApoE -/- mice treated with streptozotocin. Results Intraperitoneal injection of LXs attenuated the development of diabetes-induced albuminuria, mesangial expansion, and collagen deposition. Notably, LXs administered 10 weeks after disease onset also attenuated established kidney disease, with evidence of preserved kidney function. Kidney transcriptome profiling defined a diabetic signature (725 genes; false discovery rate P ≤0.05). Comparison of this murine gene signature with that of human diabetic kidney disease identified shared renal proinflammatory/profibrotic signals (TNF- α , IL-1 β , NF- κ B). In diabetic mice, we identified 20 and 51 transcripts regulated by LXA 4 and Benzo-LXA 4 , respectively, and pathway analysis identified established (TGF- β 1, PDGF, TNF- α , NF- κ B) and novel (early growth response-1 [EGR-1]) networks activated in diabetes and regulated by LXs. In cultured human renal epithelial cells, treatment with LXs attenuated TNF- α -driven Egr-1 activation, and Egr-1 depletion prevented cellular responses to TGF- β 1 and TNF- α Conclusions These data demonstrate that LXs can reverse established diabetic complications and support a therapeutic paradigm to promote the resolution of inflammation.

Lipoxins——A Novel Drug for Tissue Fibrosis

Therapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease.

Innate Lymphoid Cells: A Promising New Regulator In Fibrotic Diseases

New insights into the role of Klotho in inflammation and fibrosis: molecular and cellular mechanisms

Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues

TJ-M2010-5, A self-developed MyD88 inhibitor, attenuates liver fibrosis by inhibiting the NF-κB pathway

Synthesis and Biological Evaluation of 4-Oxoquinoline-3-carboxamides Derivatives As Potent Anti-Fibrosis Agents

AdipoRs- a potential therapeutic target for fibrotic disorders

Design, synthesis and biological evaluation studies of novel anti-fibrosis agents bearing sulfoxide moiety

Endogenous Pro-Resolving and Anti-Inflammatory Lipid Mediators: the New Hope of Atherosclerotic Diseases.

The role of interleukin -1 family in fibrotic diseases

Novel Biphasic Role of LipoxinA(4) on Expression of Cyclooxygenase-2 in Lipopolysaccharide-Stimulated Lung Fibroblasts.

Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Advance in Pro-Resolution Lipid Mediators and Mechanisms of Inflammation Resolution

The Impact of Inflammatory Immune Reactions of the Vascular Niche on Organ Fibrosis

Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease.

Fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage

The Injury-Related Activation of Hedgehog Signaling Pathway Modulates the Repair-Associated Inflammation in Liver Fibrosis

Cellular and Molecular Mechanisms of Intestinal Fibrosis

Lipoxin A4 promotes lung epithelial repair whilst inhibiting fibroblast proliferation